Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Any KLY news from an independent source?

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Sep 10, 2020 5:40am

161 Views

Post# 31531800

RE:RE:RE:RE:RE:RE:RE:Any KLY news from an independent source?

Yes we understand that KLY news releases are basically holy scripture to you. Those of us living in the real world and have critical thinking skills just want as much of our money back as possible. Again, is there any "truth" out there that doesn't come directly from this company or its affiliates?

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property